Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
Michael G. Silverman(Brigham and Women's Hospital), Marc S. Sabatine(Brigham and Women's Hospital)
Cited by 1,459
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.2k
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk
|Circulation|2019|930